Bliss M, Mayersohn M, Arnold T, Logan J, Michael U F, Jones W
Antimicrob Agents Chemother. 1986 Apr;29(4):649-53. doi: 10.1128/AAC.29.4.649.
Cefamandole disposition kinetics were examined in six male subjects with renal impairment who were undergoing continuous ambulatory peritoneal dialysis. Creatinine clearance values ranged from less than 1 to 11 ml/min. Cefamandole was given as a 1-g intravenous dose infused over 30 min. Cefamandole concentrations were determined in serum, urine, and dialysis fluid by a high-performance liquid chromatographic method. The following average parameter values were obtained (range): half-life, 6.1 h (4.6 to 9.7); systemic clearance, 21.9 ml/min (8.4 to 35.5); renal clearance, 11.5 ml/min (0.03 to 22.3); dialysis clearance, 0.92 ml/min (0.7 to 1.3); nonrenal clearance, 12.2 ml/min (2.9 to 27.0); volume of distribution, 0.18 liter/kg (0.09 to 0.25); steady-state volume of distribution, 0.17 liter/kg (0.09 to 0.24). Approximately 5% of the dose was dialyzed (range, 2.8 to 8.3), indicating that there is no need to supplement a dosing regimen of cefamandole due to loss by dialysis. There was a positive correlation between creatinine clearance and the terminal elimination rate constant of cefamandole (r2 = 0.41) and cefamandole renal clearance (r2 = 0.83).
在六名接受持续性非卧床腹膜透析的肾功能损害男性受试者中研究了头孢孟多的处置动力学。肌酐清除率值范围为小于1至11毫升/分钟。头孢孟多以1克静脉剂量在30分钟内输注给药。通过高效液相色谱法测定血清、尿液和透析液中的头孢孟多浓度。获得了以下平均参数值(范围):半衰期,6.1小时(4.6至9.7);全身清除率,21.9毫升/分钟(8.4至35.5);肾清除率,11.5毫升/分钟(0.03至22.3);透析清除率,0.92毫升/分钟(0.7至1.3);非肾清除率,12.2毫升/分钟(2.9至27.0);分布容积,0.18升/千克(0.09至0.25);稳态分布容积,0.17升/千克(0.09至0.24)。约5%的剂量被透析(范围,2.8至8.3),表明无需因透析丢失而补充头孢孟多的给药方案。肌酐清除率与头孢孟多的终末消除速率常数(r2 = 0.41)和头孢孟多肾清除率(r2 = 0.83)之间存在正相关。